The importance of serum levels of phosphoheksose izomerase and aldolase in cancer patients with and without lymphadenopathies

In this study, we studied serum levels of two ylycolithic enzymes, phosphoheksose izomerase and aldolase in histopatholoyically confirmed malign tumor patients, and we compared these levels between patients with and/or without metastasis and lymphadenopathy. The aim of the study is to determine the relationship between these enzymes and tumor metastasis and to assess whether they can be used as a tumor marker in the therapy and follow-up. Histopatholoyically confirmed 100 cancer patients under therapy and foil owe d-up by the Department of Radiation Oncology of Sisli Etfal Education and Research Hospital and a control group of 50 healthy individual are included in the study. In healthy control group, serum PHI enzyme levels were determined as 10-59 UIL (average 31.9 UIL), ALD levels as 1.2-6.8 UIL (average 3.81 UIL). Values obtained in patients with malign cancer were 18- 492 UIL (average 82.14 UIL) for PHI and 1.4-61.3 UIL (average 6.87 UIL) for ALD. If any classification according to tumor type was not done, PLII in 59 % of patients and ALD in 23 % of patients were above the upper limits. When such a classification was done according to tumor type, the rates of increased levels were: Lung 85.1 %, sarcoma 83.3 %, breast 60 %, gastrointestinal tract 40 %, genitourinary system 33.3 % and lymphoma 33.3 %. The rates of increased ALD levels in same tumor types were found as 40 %, 33.3 %, 16%, 13.3 %, 11.1 % and 33 % respectively. A significant difference was obtained between patient group and control group for PH! (P: 0.000) and ALD (P.O.002) levels. Levels of PHI (P.0.000) and ALD (P: 0.001) were markedly higher in patients with metastasis than in control group. When patients with metastasis and without metastasis were compared it was observed that ALD levels (P: 0.042) showed a marked difference compared to PHI levels (P: 0.128>0.05). Any significant difference was not obtained between patients with and without lymphadenopathy, cither for PHI (P: 0.154>0.05) or for ALD (P: 0.176>0.05). In conclusion, we observed that both parameters were elevated in cancer patients, aldolase levels being more significant in determining metastasis. We suggest that these parameters have the advantage of being unexpensive and easily automated.

Metastazý ve lenfadenopatisi olan ve olmayan kanserli hastalarda fosfoheksoz izomeraz ve aldolaz serum düzeylerinin önemi

Biz bu çalýþmada, glikolitik yolda yer alan fosfoheksoz izomeraz (PHI) ve aldolaz \n (ALD) serýým düzeylerini histopatolojik olarak malign tümör varlýðý saptanan hastalarda anýþtýrýp, uzak metastazý vt‘/veya lenfadenopatisi olan ve olmayan hastalarýn serumlarýnda sözkonusýý enzimlerin düzeylerini karþýlaþtýrdýk. Çalýþmanýn amacý her iki enzimin tümör metastaz iliþkisini ortaya koymak ve höylece kanser hastalýðýnýn tedavisinde ve takibinde tümör markýrlarý olarak kullanýlýp kullanýlamayacaklarýný araþtýrmaktýr. Çalýþmaya Ýstanbul, Þiþli Etfal Hastanesi Radyasyon Onkolojisi Kliniði’nde takip ve tedavileri sürdürülmekte olan histopatolojik olarak tanýlarý konulmuþ kanserli 100 hasta ve 50 saðlýklý kiþiden oluþan kontrol grubu dahil edilmiþtir. Kontrol yruhundaki saðlýklý kiþilerin serumlarýnda ekle edilen PHI düzeyleri 10-59 IHL (ortalama 31.9 UIL), ALD düzeyleri 1.2-6.005) yöre daha anlamlý olduklarý sonucuna varýldý. Lenfadenopatisi olan ve olma¬yan hastalar arasýnda, ne PLII (P: ().!54>0.05) ne de ALD (P: 0.I76>0.05) bakýmýndan anlamlý bir baðlantý ekle edilebildi. Sonuç olarak, her iki parametrenin kanserli hastalarda yülselmiþ okluðunu, Aldolaz deðerlerinin metastazý tespit etmede daha atýlmalý olduðunu izledik. Lier iki parametrenin de otomasyona kolay uygulanmasý ve ucuz oluþunuda avantaj olarak deðerlendirdik.